
GLP-1 Weight-Loss Drugs Mostly Shed Fat, Not Muscle, New Analysis Finds
A meta-analysis of 36 studies on GLP-1 and dual GLP-1/GIP agonists for weight loss shows participants lose about 9% of body weight within 3 months, with significant reductions in visceral fat and fat mass by 12 months. Lean body mass loss is present but relatively modest, suggesting muscle loss may be less of a concern than once feared. Experts emphasize maintaining protein intake and engaging in resistance and aerobic exercise to preserve muscle during GLP-1 therapy.













